Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes
Table 3
Difference of comorbidity according to the use of metformin.
Variable
Metformin user
Metformin nonuser
P
Hypertension, n (%)
417 (59.32%)
101 (66.45%)
0.120
Hypertension duration, years
5.67 ± 7.24
8.17 ± 9.97
0.004
Dyslipidemia, n (%)
436 (62.02%)
97 (63.82%)
0.713
Dyslipidemia duration, years
4.44 ± 5.22
5.50 ± 6.21
0.053
Cancer, n (%)
38 (5.43%)
17 (11.33%)
0.016
Cancer duration, years
0.40 ± 1.96
1.15 ± 3.58
0.023
Autoimmune disease, n (%)
17 (2.43%)
2 (1.33%)
0.553
Tuberculosis, n (%)
21 (3%)
9 (6%)
0.086
Depression, n (%)
18 (2.57%)
9 (6%)
0.039
Periodontal disease, n (%)
72 (10.29%)
26 (17.33%)
0.023
Results are expressed as mean ± standard deviation or n (%). P value for the t-test or the chi-square test comparing both the groups with and without metformin.
